new glp-1 drug Comparing Ozempic, Wegovy and Other Drugs The next generation of GLP-1

It has no approved medical or human use and must not be used for personal consumption

12 semanas de suplementacin con CLA (3,2 a 6,4 gramos por da) redujeron la masa de grasa corporal, el porcentaje de grasa corporal, las medidas de resistencia a la insulina (y el azcar en sangre en ayunas), as como los niveles de leptina (hormona de la saciedad), en 48 adultos obesos

While retatrutide is being developed primarily as an obesity and diabetes treatment, the triple-agonist mechanism has implications beyond weight loss

For preclinical tissue models, stronger evidence would require standardized injury models, blinded outcome assessment, histological confirmation, functional endpoints, and comparison against appropriate positive and negative controls